Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat (NASDAQ:SGMT)
· seekingalpha.com
Sagimet Biosciences Inc. gets a Buy rating as denifanstat targets MASH & acne; key Phase 3 catalysts and funding risks ahead. Click for more on SGMT stock.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...